Protalix BioTherapeutics, Inc.

AMEX (USD): Protalix BioTherapeutics, Inc. (PLX)

Last Price

1.40

Today's Change

-0.01 (0.70%)

Day's Change

1.33 - 1.41

Trading Volume

327,256

Overview

Market Cap

102 Million

Shares Outstanding

73 Million

Avg Volume

188,651

Avg Price (50 Days)

1.11

Avg Price (200 Days)

1.18

PE Ratio

-6.09

EPS

-0.23

Earnings Announcement

14-Nov-2024

Previous Close

1.41

Open

1.38

Day's Range

1.33 - 1.41

Year Range

0.82 - 1.9

Trading Volume

327,735

Price Change Highlight

1 Day Change

-0.71%

5 Day Change

18.64%

1 Month Change

28.44%

3 Month Change

44.15%

6 Month Change

22.81%

Ytd Change

-23.08%

1 Year Change

0.00%

3 Year Change

32.08%

5 Year Change

-45.74%

10 Year Change

-93.46%

Max Change

-99.84%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Discussions
Be the first to like this. Showing 3 of 3 comments

ysabag

with the new ceo it will raise above the target

2014-07-29 14:51

Tygobar

Yes, medical startups usually should very very good in everything like that really and totally , yet you do have very low price of the stock here, how can you really even describe this ? Could you damn let me know this please. I am all ears for example.

2019-09-01 13:12

Lalis

I do hope that medical things will be really our future and not just cause it cause something for example good for now, but in the real perspective for many many generations ahead totally. But for now of course I plan to invest a lot in such things.

2019-09-07 13:56

Post a Comment